-transparent.png){kind=logo}
Bronchomotor tone is, in part, under beta-adrenergic control, and beta-adrenergic agonists are commonly used in the therapy for chronic obstructive pulmonary disease (COPD). Beta-adrenergic blockade with propranolol is contraindicated in asthmatic patients, yet little is known of its effect in patients with COPD. We studied 13 patients with COPD in a random-entry, double-blind crossover comparison of oral propranolol, 40 mg, and oral placebo on separate day. Pulmonary function worsened after administration of propranolol. Significant differences were present between the drugs' effect on heart rate, airway resistance, specific resistance, and flow rates at one hour, and persisting through four hours (p less than 0.01). Propranolol may have a deleterious effect on pulmonary function in nonasthmatic COPD. We conclude that when propranolol is to be used in patients with COPD, the short- and long-term effects on airway should be measured sequentially.
E H Chester, and
H J Schwartz, and
G M Fleming
January 1986,
European journal of clinical pharmacology,
E H Chester, and
H J Schwartz, and
G M Fleming
March 1975,
Chest,
E H Chester, and
H J Schwartz, and
G M Fleming
June 2023,
Cell host & microbe,
E H Chester, and
H J Schwartz, and
G M Fleming
September 2004,
American journal of respiratory and critical care medicine,
E H Chester, and
H J Schwartz, and
G M Fleming
November 2001,
American journal of respiratory and critical care medicine,
E H Chester, and
H J Schwartz, and
G M Fleming
October 1965,
The American review of respiratory disease,
E H Chester, and
H J Schwartz, and
G M Fleming
March 1981,
Harefuah,
E H Chester, and
H J Schwartz, and
G M Fleming
November 1984,
European journal of radiology,
E H Chester, and
H J Schwartz, and
G M Fleming
November 1976,
Deutsche medizinische Wochenschrift (1946),
E H Chester, and
H J Schwartz, and
G M Fleming
January 1976,
Scandinavian journal of respiratory diseases,
